|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Mortgage loans | ||||||||||||||||||||
| Residential mortgage loans - at fair value | ||||||||||||||||||||
| Residential mortgage loans in securitization trusts - at fair value | ||||||||||||||||||||
| Commercial mortgage loans | ||||||||||||||||||||
| CMBS, at fair value | ||||||||||||||||||||
| RMBS - at fair value | ||||||||||||||||||||
| CMBS | ||||||||||||||||||||
| U.S. Treasury securities | ||||||||||||||||||||
| Total cMBS, at fair value | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Principal and interest receivable | ||||||||||||||||||||
| TBA securities and interest rate futures contracts - at fair value | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||||||||||||||
| LIABILITIES | ||||||||||||||||||||
| Notes payable | ||||||||||||||||||||
| Non-recourse securitization obligation, collateralized by residential mortgage loans in securitization trusts (see Note 2) | ||||||||||||||||||||
| Securities sold under agreements to repurchase | ||||||||||||||||||||
| U.S. Treasury securities | ||||||||||||||||||||
| Total securities sold under agreements to repurchase | ||||||||||||||||||||
| Senior unsecured notes | ||||||||||||||||||||
| TBA securities and interest rate futures contracts - at fair value | ||||||||||||||||||||
| Due to broker | ||||||||||||||||||||
| Accrued expenses | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Affiliates | ||||||||||||||||||||
| Interest payable | ||||||||||||||||||||
| Income taxes payable | ||||||||||||||||||||
| Management fee payable to affiliate | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Affiliates | ||||||||||||||||||||
| Total management fee payable to affiliate | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| STOCKHOLDERS' EQUITY | ||||||||||||||||||||
| Common stock, $0.01 par value. As of June 30, 2026: 350,000,000 shares authorized, 23,178,979 shares issued and outstanding. As of December 31, 2025: 350,000,000 shares authorized, 24,914,647 shares issued and outstanding. | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive income (loss) | ||||||||||||||||||||
| Retained earnings (deficit) | ||||||||||||||||||||
| Total stockholders' equity | ||||||||||||||||||||
| Total liabilities and stockholders' equity | ||||||||||||||||||||
| Common stock issued (shares) | ||||||||||||||||||||
Loading...